SCHEMBL4841932

SCHEMBL4841932

CCN(CC(O)NC(C)=O)c1ccc(C=C(C)C(=O)O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.48
TSHR P16473 1/20 0.48
AKR1C3 P42330 1/20 0.42
MAPT P10636 5/20 0.40
KDM4E B2RXH2 4/20 0.40
GAA P10253 4/20 0.40
GLA P06280 2/20 0.40
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
POLB P06746 4/20 0.40
CNR2 P34972 2/20 0.39
ALDH3A1 P30838 1/20 0.39
ALDH1A3 P47895 1/20 0.39
LMNA P02545 3/20 0.38
MAPK1 P28482 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
USP2 O75604 1/20 0.38
RECQL P46063 1/20 0.38
BLM P54132 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4908782 0.83 AKR1C3 (0.45) ALDH1A1TSHRAKR1C3MAPTKDM4E
SCHEMBL10629619 0.82 ALDH1A1 (0.56) ALDH1A1TSHRAKR1C3MAPTKDM4E
SCHEMBL26332147 0.82 ALDH1A1 (0.56) ALDH1A1TSHRAKR1C3MAPTKDM4E
SCHEMBL9658870 0.74 AKR1C3 (0.53) ALDH1A1AKR1C3MAPTKDM4EGAA
SCHEMBL10981268 0.72 ALDH1A1 (0.58) ALDH1A1TSHRMAPTKDM4EGAA
SCHEMBL10981269 0.72 ALDH1A1 (0.58) ALDH1A1TSHRMAPTKDM4EGAA
SCHEMBL15442885 0.72 AKR1C3 (0.50) ALDH1A1AKR1C3MAPTKDM4EGAA
SCHEMBL26332150 0.72 AKR1C3 (0.50) ALDH1A1AKR1C3MAPTKDM4EGAA
SCHEMBL222105 0.69 ALDH1A1 (0.64) ALDH1A1TSHRMAPTKDM4EGAA
SCHEMBL2462984 0.69 AKR1C3 (0.82) ALDH1A1AKR1C3KDM4EGLAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7449315-B2 Bifunctional energy-reversible acyl-compositions CRYOLIFE, INC. (US) 2008-11-11 US disclosed
US-20070167644-A1 BIFUNCTIONAL ENERGY-REVERSIBLE ACYL-COMPOSITIONS CRYOLIFE, INC. (US) 2007-07-19 US disclosed
EP-1392204-A4 BIFUNCTIONAL ENERGY-REVERSIBLE ACYL-COMPOSITIONS CRYOLIFE INC (US) 2007-07-18 EP disclosed
US-7157458-B2 Bifunctional energy-reversible acyl-compositions CRYOLIFE, INC. (US) 2007-01-02 US disclosed
US-20060106204-A1 Bifunctional energy-reversible acyl-compositions GILBERT CARL W 2006-05-18 US disclosed
EP-1392204-A2 BIFUNCTIONAL ENERGY-REVERSIBLE ACYL-COMPOSITIONS CryoLife, Inc. (US) 2004-03-03 EP disclosed
US-20020187993-A1 Bifunctional energy-reversible acyl-compositions CRYOLIFE, INC. 2002-12-12 US disclosed
WO-2002083030-A2 BIFUNCTIONAL ENERGY-REVERSIBLE ACYL-COMPOSITIONS CRYOLIFE, INC. (US) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020187993-A1 Bifunctional energy-reversible acyl-compositions ACACB, ACACA, ACAT1 ALDH1A1 951/4885TSHR 3892/4885AKR1C3 1146/4885
US-20070167644-A1 BIFUNCTIONAL ENERGY-REVERSIBLE ACYL-COMPOSITIONS ACACB, ACAT1, ACACA ALDH1A1 1248/4885TSHR 3775/4885AKR1C3 1024/4885
US-20060106204-A1 Bifunctional energy-reversible acyl-compositions ACACB, ACAT1, ACACA ALDH1A1 1248/4885TSHR 3775/4885AKR1C3 1024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.